Thompson Siegel & Walmsley LLC Increases Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Thompson Siegel & Walmsley LLC increased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 565,337 shares of the company’s stock after buying an additional 51,705 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 0.08% of Roivant Sciences worth $6,688,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Nordea Investment Management AB boosted its holdings in Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences in the third quarter valued at $46,333,000. Barclays PLC boosted its holdings in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in Roivant Sciences by 13.3% in the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after purchasing an additional 458,601 shares during the last quarter. Finally, Retirement Systems of Alabama boosted its holdings in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after purchasing an additional 112,286 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent analyst reports. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Roivant Sciences presently has an average rating of “Buy” and an average target price of $18.08.

Roivant Sciences Stock Down 1.7 %

ROIV opened at $10.42 on Friday. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06. The company has a 50-day moving average price of $10.83 and a 200 day moving average price of $11.52. The company has a market cap of $7.44 billion, a PE ratio of -69.46 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the sale, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,551,654.85. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CIO Mayukh Sukhatme sold 185,946 shares of the stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the completion of the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at approximately $226,038,564. The trade was a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,388,170 shares of company stock worth $27,612,299 in the last 90 days. Insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.